Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.58 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791922 | 0.90 | KDM4E (0.57) | CNR1CNR2KDM4EMEN1MAPT | |
| SCHEMBL4612148 | 0.86 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL3816975 | 0.86 | CNR2 (0.58) | CNR1CNR2 | |
| SCHEMBL3822724 | 0.86 | CNR1 (0.47) | CNR1CNR2ALOX5ALOX5AP | |
| SCHEMBL3828981 | 0.85 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL3249853 | 0.85 | CNR1 (0.73) | CNR1CNR2KDM4EMEN1MAPT | |
| SCHEMBL3827684 | 0.81 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL14164187 | 0.81 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL4247698 | 0.79 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL4612428 | 0.79 | CNR2 (0.49) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |